ClinConnect ClinConnect Logo
Search / Trial NCT01871064

Residual Curarization and Its Incidence at Tracheal Extubation in China

Launched by XINMIN WU · Jun 5, 2013

Trial Information

Current as of June 06, 2025

Completed

Keywords

Laparotomy Laparoscopic Surgery General Anesthesia Neuromuscular Block

ClinConnect Summary

This is a prospective, multi-site, anesthesiologist and PACU nurse TOF-Watch SX® blinded observational study of surgical patients undergoing elective laparoscopic or open abdominal procedures requiring general anesthesia and non-depolarizing neuromuscular blockade. There are two temporal aspects to the data collection: a prospective data collection in the OR and PACU; and a retrospective chart review one week after hospital discharge.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age≥18;
  • American Society of Anesthesiologists(ASA) class 1-3;
  • Scheduled for elective open or laparoscopic abdominal surgery that is anticipated to last less than 4 hours;
  • Administration of general anesthesia and ≥ 1 dose of non-depolarizing neuromuscular blockers for endotracheal intubation or maintenance of neuromuscular blockade;
  • Planned for extubation to occur in the OR;
  • Signed informed consent.
  • Exclusion Criteria:
  • Redo surgery on the same hospital admission;
  • Pre-established need or expected to require post-operative mechanical ventilation;
  • Conditions, surgical procedures, or participant positioning that may interfere with TOF-Watch SX® operation, calibration, or accuracy;
  • Anesthesiologist use of objective neuromuscular monitoring during surgery (e.g. mechanomyography, electromyography or related method);
  • Pregnancy;
  • Participation in any other clinical trial;
  • Member or a family member of the personnel of the investigational or Sponsor staff directly involved with this trial.

About Xinmin Wu

Xinmin Wu is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapeutics and enhancing patient care, Xinmin Wu actively collaborates with healthcare professionals, research institutions, and regulatory bodies to design and implement robust clinical trials. The organization prioritizes ethical standards, patient safety, and scientific integrity, ensuring that all studies are conducted with the utmost diligence and transparency. Through its comprehensive approach, Xinmin Wu aims to contribute significantly to the improvement of health outcomes and the advancement of medical science.

Locations

Beijing, , China

Beijing, , China

Hangzhou, Zhejiang, China

Beijing, , China

Chengdu, Sichuan, China

Beijing, , China

Shanghai, , China

Shenyang, Liaoning, China

Beijing, , China

Wuhan, Hubei, China

Shanghai, , China

Beijing, , China

Jinan, Shandong, China

Shanghai, , China

Guangzhou, Guangdong, China

Wuhan, Hubei, China

Zhengzhou, Henan, China

Guangzhou, Guangdong, China

Changsha, Hunan, China

Guangzhou, Guangdong, China

Nanjing, Jiangsu, China

Yangzhou, Jiangsu, China

Changchun, Jilin, China

Xi'an, Shanxi, China

Urumqi, Xinjiang, China

Hangzhou, Zhejiang, China

Hangzhou, Zhejiang, China

Hangzhou, Zhejiang, China

Wenzhou, Zhejiang, China

Chongqing, , China

Shanghai, , China

Shanghai, , China

Patients applied

0 patients applied

Trial Officials

Xinmin Wu, MD

Principal Investigator

Peking University First Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials